

ACTAVIS V ELI LILLY - SHOULD WE HAVE SEEN IT COMING?

18 September 2017

The UK Supreme Court's 12 July 2017 judgment in *Actavis v Eli Lilly* is undoubtedly a landmark decision, re-steering UK law regarding patent infringement by introducing a doctrine of equivalents.

But a systematic review of the law in this area over the last two decades shows that the writing has long been on the wall, so to speak. Lord Neuberger's first instance judgment in the *Kirin-Amgen* case, as long ago as 2001, is particularly illuminative.

When seeking to understand how the courts will interpret Lord Neuberger's *Actavis v Eli Lilly* judgment, the best informed will understand what has come before, and why. To help condense this understanding, we have prepared an article looking at the evolution of the law in this area, and considering the light it throws on the likely path of the jurisprudence from here.

[Actavis v Eli Lilly - Should We Have Seen It Coming?](#) is the first in a series of analysis pieces that we are publishing considering the implications of the Supreme Court's judgment - but the rest will be shorter than this one! We will be looking at the judgment from all angles, including the international reach of the decision and some unlikely parallels with trademark law. Watch this space!

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.

Related Intellectual Property

Author(s)

Gordon Harris

Partner - International IP Leadership,
London

 Email

gordon.harris@gowlingwlg.com

 Phone

+44 (0)20 3636 8063

 vCard

Gordon Harris